AI-based AML risk stratification using next generation cytogenomics
Ended Project Grant Awarded Last action
- Award ID
- R44CA278140
- Recipient
-
Phase Genomics Inc. UEI TQ67ST6YELX5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,000,000
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date
- Originally
- Place of performance
- Washington, USA
Award details come from USAspending.gov.
Description
- Abstract
- Chromosome aberrations are a hallmark of acute myeloid leukemia and offer mechanistic and prognostic insights into disease. As such, a combination of cytogenetic assays are routinely applied as a part of the AML diagnostic workflow. While offering invaluable information on disease severity, most chromosome aberrations fall into the "cytogenetic abnormalities not classified" or "complex karyotype" categories. A range of studies have shown that, while ambiguous, these variants have prognostic value, suggesting the existence of cryptic variants of significance or complex epistases that drive the AML phenotype. However, there is currently no system for translating genome-wide chromosomal aberration information into patient risk. To improve the predictive potential of chromosome aberration profiles, we propose the development of a risk-prediction metric that will add new prognostic value to AML studies. Specifically, we will produce a method which will establish a patient risk metric that can help guide treatment decisions for patients traditionally judged as of intermediate risk. This development will employ our scalable cytogenomic tools and novel machine learning analytics to generate a large collection of cytogenomic datasets and analyze them to identify patterns linked to AML phenotypes. Once completed, we will have a combined kit and software solution that will not only improve upon existing cytogenetic applications in AML, but will offer new prognostic insights beyond what is possible with current tools. This product will deliver high-resolution view of the chromosome aberration landscape in AML and an offer a data-driven interpretation of how variants will impact disease severity.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,000,000 | |
| Amendment | $1,000,000 | |
| Original award | $1,000,000 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Fred Hutchinson Cancer Center | $85,953 |
Quick answers
Who received award R44CA278140?
R44CA278140 was awarded to Phase Genomics Inc. by National Cancer Institute (National Institutes of Health) on July 1, 2023.
How much is award R44CA278140 worth?
$3,000,000 has been obligated on R44CA278140.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award